The findings come from the tenth edition of the company’s Prescription Dermatological Drugs report.
“This is an exciting time in dermatology as there continues to be a shift in the understanding of the pathophysiology of many skin diseases,” said Mary Ann Crandall. “And there’s new biologics and their uses in dermatology.”
Crandall also said there are new trends such as a movement toward dispensing prescription dermatology agents in the office.
Another interesting area is the growth in the demand for platelet rich plasma. When PRP is injected into the damaged area, it stimulates the tissue, causing mild inflammation that triggers a healing cascade. This area of medicine has blossomed due to an increase in skin cancer incidence, new exciting biologics for psoriasis, increased demand by baby boomers (both men and women) for antiaging products, consolidation within the industry and strong late stage pipeline entities, said Kalorama.
The worldwide market for prescription dermatological drugs encompasses a wide variety of products that treat disorders of the skin as well as the effects of aging. The field of dermatology is currently experiencing a busy and interesting period and, as a result, the range of therapeutic options available to physicians has expanded.
According to Kalorama, while there are a number of companies participating in the worldwide market for prescription dermatological drugs—ranging from large international pharmaceutical companies, small niche pharmaceutical companies to generic companies both large and small—there is also competitive pressure from over-the-counter (OTC) participants. However, even with the availability of OTC products, manufacturers of prescription products continue to do well in terms of revenues. Demand for products in the prescription dermatological market will likely remain high due to the aging population and the quest for lifestyle treatments to meet the needs of aging baby boomers. Competitors are increasingly offering products that meet this need, which is an entirely different concept than other products that the companies may offer.